HC Wainwright Predicts Cytosorbents Q1 Earnings

Cytosorbents Co. (NASDAQ:CTSO - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Cytosorbents in a note issued to investors on Thursday, April 3rd. HC Wainwright analyst S. Lee forecasts that the medical research company will earn ($0.08) per share for the quarter. HC Wainwright has a "Neutral" rating and a $1.00 price objective on the stock. The consensus estimate for Cytosorbents' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents' Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.24) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.11) EPS.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. The company had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.

CTSO has been the subject of a number of other research reports. StockNews.com assumed coverage on Cytosorbents in a report on Friday. They issued a "hold" rating for the company. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Cytosorbents presently has an average rating of "Moderate Buy" and a consensus price target of $4.67.

Remove Ads

Cytosorbents Stock Up 3.4 %

Shares of CTSO traded up $0.03 on Monday, reaching $0.97. The stock had a trading volume of 110,425 shares, compared to its average volume of 144,179. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The firm has a market capitalization of $60.75 million, a price-to-earnings ratio of -2.70 and a beta of 1.17. The company has a 50-day simple moving average of $1.06 and a 200-day simple moving average of $1.02.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CTSO. Geode Capital Management LLC increased its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after acquiring an additional 32,415 shares in the last quarter. Skylands Capital LLC grew its position in Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock valued at $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Millennium Management LLC bought a new stake in Cytosorbents during the 4th quarter valued at about $30,000. Key Client Fiduciary Advisors LLC raised its holdings in Cytosorbents by 127.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after buying an additional 43,900 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.